Quick Facts

• Primary Use: Management of mild to moderate ulcerative colitis.
• Key Function: Supports the induction of remission in active disease.
• Long-Term Function: Helps maintain clinical remission in ulcerative colitis.

Colitofalk is a prescription medication utilized in the management of inflammatory bowel disease. Its primary approved therapeutic domain involves addressing ulcerative colitis (UC), a condition characterized by inflammation in the large intestine and rectum.

The medication is indicated for use in adult patients to help induce clinical remission during active phases of mild to moderate ulcerative colitis. Following the successful management of active disease, Colitofalk is also prescribed for long-term use to support the maintenance of remission, which may help reduce the recurrence of symptoms. Adherence to a regimen may support patient well-being and help to manage the course of the condition.

Regulatory References

1. NIH MedlinePlus guidance

Who Can and Cannot Use Colitofalk?

This section defines population eligibility for Colitofalk (Mesalazine) based strictly on official governmental regulatory documents.

---

Absolute Contraindications

Colitofalk must not be used by individuals with a known or suspected hypersensitivity to salicylates (e.g., aspirin), aminosalicylates (mesalazine), or any other ingredient in the specific formulation. This represents an absolute regulatory exclusion.

---

Eligibility by Age and Condition

Population Group	Regulatory Eligibility Status
Adults	Approved for induction and maintenance of remission.
Pediatric Patients	Approved for use, typically restricted to those 5 years of age and older or meeting a minimum weight (e.g., 24 kg), as efficacy is not established below these thresholds.
Renal or Hepatic Impairment	Restricted/Conditional Use. Requires caution and mandated evaluation of organ function prior to and periodically during treatment.
Pregnancy and Lactation	Conditional Use. Permitted only if the treating healthcare provider determines the potential benefit justifies the potential risk, as mesalazine is excreted in breast milk.

---

Further Restrictions

Use is generally avoided in patients with upper gastrointestinal tract obstruction due to the drug’s delayed-release mechanism. Furthermore, use requires monitoring in patients taking nephrotoxic drugs due to increased risk to the kidneys, as explicitly stated in product labeling.

Colitofalk, containing the active ingredient Mesalazine, has officially documented interaction patterns focused primarily on pharmacodynamic reinforcement and one specific laboratory interference, rather than metabolic enzyme pathways. No formal contraindications for co-administration are universally listed in regulatory documents.

Documented Pharmacodynamic Interactions

• Thiopurines: Co-administration with thiopurines, such as Azathioprine or 6-Mercaptopurine, may enhance myelosuppressive effects and increase the risk for blood disorders. This interaction involves an increase in the concentration of the active cytotoxic metabolite of the thiopurines (6-TGN).
• Nephrotoxic Agents: Concurrent use with known nephrotoxic agents, which include Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), may increase the risk of nephrotoxicity (adverse effects on kidney function). Monitoring for changes in renal function is advised in this context.
• Anticoagulants: Official labeling notes that Mesalazine may potentially potentiate the effects of coumarin-type anticoagulants, such as Warfarin, necessitating caution.

Interaction-Related Constraints

The interaction profile includes a population-specific note: patients with known renal impairment should have the risks and benefits of co-administration with other nephrotoxic drugs evaluated closely. Additionally, Mesalazine may interfere with laboratory tests, potentially causing spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection.

Colitofalk (Mesalazine) exerts its pharmacological action through a localized, multi-target anti-inflammatory mechanism focused exclusively on the colonic and rectal mucosa. Its action is strictly peripheral and dependent on achieving high concentrations directly at the site of biological activity.

---

Enzyme Inhibition and Oxidative Stress Neutralization

The primary action involves Mesalazine's role as a non-competitive inhibitor of both Cyclooxygenase (COX) and Lipoxygenase (LOX) enzymes, curtailing the local production of pro-inflammatory prostaglandins and leukotrienes. Furthermore, the molecule acts as a direct antioxidant, actively scavenging damaging Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS), which mitigates cellular damage caused by excessive oxidative stress.

---

Modulation of Inflammatory Gene Signaling

Beyond enzyme inhibition, the drug modulates the core mechanisms of cellular inflammation by inhibiting the activation of the NF-kappaB transcription factor and acting as an agonist for PPAR-gamma (Peroxisome Proliferator-Activated Receptor gamma). This dual nuclear action downregulates the overall expression of pro-inflammatory cytokines and chemokines, thereby limiting the chemical signals that drive immune cell recruitment and activation.

---

Physiological Consequence of Localized Action

The synergistic inhibition of inflammatory mediators and the stabilization of the cellular environment diminish the flow and activation of immune cells into the gut wall. This mechanistic cascade results in the core physiological effect of stabilizing the epithelial barrier and mitigating mucosal edema and erythema, which is a key element of the observed physiological changes. The mechanism is entirely dependent on the delivery system ensuring topical contact with the biologically relevant tissue.

How Colitofalk is Used: Administration Guidelines

Colitofalk (Mesalazine) is administered according to specific guidelines that determine the route, dosage, and frequency based on the treatment goal. Administration is generally divided between the Oral route, using delayed-release tablets or capsules for widespread colonic delivery, and the Rectal route, using suppositories or enemas for localized application to the distal colon or rectum.

Dosing and Regimen Patterns

The required dosage is structured around the phase of the condition being managed. Induction of remission for active disease typically involves higher oral dose ranges, often between 2.4 g/day and 4.8 g/day for a finite, short-term course, such as six to eight weeks. For maintenance of remission and preventing symptom recurrence, a long-term, continuous oral dosage of 1.5 g/day to 2.4 g/day is usually prescribed.

Oral doses may be administered either as divided doses multiple times a day or, depending on the specific formulation, as a single once-daily dose. Rectal administration, such as a 4 g enema, is typically administered once daily, often at bedtime to facilitate retention overnight.

Administration Requirements and Special Conditions

To preserve the delayed-release mechanism designed for targeted delivery to the lower bowel, oral tablets and capsules must be swallowed whole and must not be crushed, cut, or chewed. Patients receiving rectal forms are usually instructed to empty their bowels before use and retain the product for a prescribed duration. If a dose is missed, patients should resume the regular schedule and must not double the next dose to compensate. For the pediatric population, dosing is often calculated based on body weight (mg/kg/day), not exceeding the maximum adult dose, and specific monitoring of renal function is instructed prior to and during treatment.

Colitofalk: Recent Clinical Evidence

---

Research Focus

Research has investigated how the agent functions, particularly in preclinical models, focusing on its influence on inflammatory pathways. This line of inquiry explored the agent's relationship with disease progression, with studies exploring measured changes in symptom severity as a primary endpoint.

Clinical Studies in Adults

Clinical studies evaluated whether the agent was associated with changes in patient-reported pain scores in adults experiencing acute flares. Research also compared the time course of observed effects relative to placebo, with findings from Phase 3 trials analyzed to characterize the typical magnitude and duration of recorded changes.

Studies explored the agent's action in relation to inflammation in a cohort of adults with persistent conditions, comparing outcomes to those observed with standard treatments. The goal was to assess its role in chronic condition management.

Studies in Pediatric Populations

Limited studies have examined changes in respiratory function in children with moderate to severe illness. Research has also investigated changes in reported pain following administration in a small pediatric group; these findings are awaiting confirmation from larger studies to establish broader relevance.

Safety and Tolerability Data

Research has analyzed the agent's tolerability during long-term investigation in adults, with results indicating that most adverse events recorded were mild to moderate in severity. Research reports that the most common adverse events recorded across clinical trials were headache, nausea, and localized irritation at the administration site. Data regarding the safety profile in pregnant or breastfeeding individuals are currently limited.

Common questions about Colitofalk (FAQ)

---

Q: Are there any long-term side effects associated with Colitofalk use?

Official product information notes that chronic use of mesalazine is associated with potential risks of renal impairment (kidney damage) and changes to blood cell counts (blood dyscrasias). Because of these potential risks, monitoring of kidney function and blood cell counts may be recommended periodically during long-term therapy, especially for older adults or those taking interacting drugs.

---

Q: Is Colitofalk used for any other conditions besides its main treatment area?

The approved indications for mesalazine products are limited to treating active mild to moderate ulcerative colitis (UC), which includes inflammation in the rectum (proctitis) and sigmoid colon (proctosigmoiditis). It is also approved for the maintenance of remission in UC. Official regulatory labels do not list any other conditions for which this drug is approved.

---

Q: Can older adults use Colitofalk?

The medicine is generally approved for use in the adult population, which includes the elderly. However, official safety notes indicate that geriatric patients may have an increased potential for blood dyscrasias (blood disorders). For this reason, monitoring of blood cell counts is often considered for older individuals during treatment.

---

Q: Are there known interactions between Colitofalk and common cold medications?

Official labeling states that mesalazine products are known to interact with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a type of pain reliever often found in cold and flu remedies. Concurrent use with NSAIDs may increase the risk of nephrotoxicity (adverse effects on the kidneys). Monitoring of renal function may be recommended when this type of interaction is present.

---

Q: Can people with a history of allergies use Colitofalk?

The medicine is absolutely contraindicated (must not be used) if an individual has a known or suspected hypersensitivity to salicylates (like aspirin), aminosalicylates, or any non-active ingredient in the specific formulation. A history of other allergies is important health information to share with a healthcare provider.

---

Q: Does Colitofalk cause any changes to skin or hair?

Adverse reactions related to the skin and hair have been reported. These include rash, itching (pruritus), acne, and hair loss (alopecia). Additionally, rare, but serious Severe Cutaneous Adverse Reactions (SCARs) have been noted in the official safety profile.

---

Q: Do food or certain types of meals change how Colitofalk works?

Mesalazine delayed-release formulations may generally be taken with or without food. While taking the medicine with a high-fat meal can slightly increase the amount of mesalazine absorbed systemically, this difference is generally not thought to affect the clinical outcome significantly at standard doses.

---

Q: Does Colitofalk make people feel tired or fatigued?

Yes, regulatory documents list fatigue (feeling very tired) as one of the commonly reported adverse reactions in clinical trials. Dizziness is also listed among the possible side effects.

---

Q: Is Colitofalk a generic drug or a brand-name drug?

Colitofalk is a registered brand-name medicinal product. The active ingredient it contains, Mesalazine (chemically known as 5-Aminosalicylic Acid or 5-ASA), is the generic name for the drug compound.

---

Q: How long after starting Colitofalk can side effects appear?

Official safety information indicates that serious reactions, such as acute intolerance syndrome and hypersensitivity reactions, have been reported to occur shortly after the initiation of treatment. Other potential adverse effects, especially those affecting the kidneys or blood, may be monitored periodically as part of long-term management.

---

Q: Does Colitofalk have a warning about driving or operating machinery?

The product labeling notes that some patients may experience adverse reactions such as dizziness or fatigue. If these side effects occur, official safety information recommends caution before driving or operating machinery.

---

Q: Is Colitofalk addictive?

According to official regulatory documents, mesalazine is not classified as a controlled substance. The product is not generally associated with potential for abuse or the development of physical dependence.

---

Q: Is Colitofalk a type of immunosuppressant?

Mesalazine (5-ASA) is primarily classified as an aminosalicylate anti-inflammatory agent. While the drug does modulate inflammatory pathways at the site of inflammation, regulatory documents do not typically classify it as an immunosuppressant.

---

Q: Can Colitofalk affect fertility (informational question)?

Non-clinical toxicology studies focusing on reproductive effects in animals found that mesalazine had no effect on fertility or reproductive performance in male and female rats. This information is based on testing done at high doses relative to the recommended human dose.

Official Storage and Disposal Requirements

Storage of Colitofalk (mesalazine) is dictated by its formulation to ensure stability and efficacy. All forms must be kept out of the sight and reach of children.

---

Storage Conditions

Formulation	Temperature Limit	Protection Requirements
Gastro-resistant Tablets	Store below 25 C	Keep container tightly closed to protect from moisture
Rectal Suspension (Enema)	Store at Controlled Room Temperature; Do not freeze	Store in the original package to protect from light

---

Stability and Disposal

The rectal suspension must be discarded if the contents become dark brown [Source 1.1, 2.3]. Unused or expired Colitofalk must be disposed of safely according to regulatory instructions. Patients should not throw away this medicine via household waste or wastewater [Source 3.6]. Instead, consult a pharmacist or utilize an authorized drug take-back option for proper pharmaceutical waste handling [Source 1.4, 3.6].